Vapotherm to Present at the Canaccord Genuity 40th Annual Growth Conference

Vapotherm is scheduled to present at 10:30 am Eastern Time.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Thursday, August 6, 2020
Information
Tags: 
Medical devices, Manufacturing, Other Manufacturing, Health, Medical Supplies, Medical specialties, Medical emergencies, Respiratory diseases, Medicine, Health care, Respiratory therapy, Diving medicine, Hypercapnia, Vapotherm, Shortness of breath, Ventilator, New York Stock Exchange
Geotags: 
NEW HAMPSHIRE, United States
⚠generated by AI ↴
Summary
Key Points: 
  • Vapotherm is scheduled to present at 10:30 am Eastern Time.
  • Vapotherm, Inc. (NYSE: VAPO) is a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, USA.
  • Vapotherm high velocity therapy is mask-free noninvasive ventilatory support and is a front-line tool for relieving respiratory distressincluding hypercapnia, hypoxemia, and dyspnea.
  • Website Information Vapotherm routinely posts important information for investors on the Investor Relations section of its website, http://investors.vapotherm.com/ .


Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary high velocity therapy, which is used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be presenting at the Canaccord Genuity 40th Annual Growth Conference on Thursday, August 13, 2020 via webcast.

Vapotherm is scheduled to present at 10:30 am Eastern Time. The presentation will be accessible via a live webcast at: http://wsw.com/webcast/canaccord42/vapo/.

A webcast replay of the presentation will be available for 90 days following the presentation in the Event Archive section of Vapotherm’s Investor website at http://investors.vapotherm.com/.

Vapotherm, Inc. (NYSE: VAPO) is a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, USA. The company develops innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders. Over 2.3 million patients have been treated with Vapotherm high velocity therapy. For more information, visit www.vapotherm.com.

Vapotherm high velocity therapy is mask-free noninvasive ventilatory support and is a front-line tool for relieving respiratory distress—including hypercapnia, hypoxemia, and dyspnea. It allows for the fast, safe treatment of undifferentiated respiratory distress with one user-friendly tool. The Precision Flow system’s mask-free interface delivers optimally conditioned breathing gases, making it comfortable for patients and reducing the risks and care complexities associated with mask therapies. While being treated, patients can talk, eat, drink and take oral medication.

Website Information Vapotherm routinely posts important information for investors on the Investor Relations section of its website, http://investors.vapotherm.com/. Vapotherm intends to use this website as a means of disclosing material, non-public information and for complying with Vapotherm’s disclosure obligations under Regulation FD. Accordingly, investors should monitor the Investor Relations section of Vapotherm’s website, in addition to following Vapotherm’s press releases, Securities and Exchange Commission filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, Vapotherm’s website is not incorporated by reference into, and is not a part of, this document.

Copyright: 
Copyright Business Wire 2020